Erik Linklater

Erik Linklater, PhD, is a Senior Scientist in the Cell Group at PPD, where they apply their expertise in cell and molecular biology to develop innovative tools for disease prevention and therapy. Previously, they worked as a Research Assistant at Van Andel Institute, where they studied the role of the HGF receptor MET in triple-negative breast cancer. Erik also held positions as a Postdoctoral Researcher and Graduate Student Researcher at the University of Colorado Anschutz Medical Campus, focusing on cancer cell invasion mechanisms. Their academic journey began with an undergraduate research assistantship at Michigan State University, where they investigated the effects of mutations on the tumor suppressor protein p53. Erik holds a Bachelor of Science in Biochemistry and Molecular Biology from Michigan State University and a PhD in Molecular Biology from the University of Colorado Anschutz Medical Campus.